Skip to content

Evaluation of Smartphone-based Monitoring as a Biomarker of Deep-brain Stimulation Response in Parkinson’s disease

Evaluation of Smartphone-based Monitoring as a Biomarker of Deep-brain Stimulation Response in Parkinson’s disease - SmartDBS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00025816
Enrollment
60
Registered
2021-07-09
Start date
2021-05-10
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20.90

Interventions

Group 1: Patients diagnosed with idiopathic Parkinson's syndrome who are planning to undergo deep brain stimulation for the treatment of symptoms.

Sponsors

Universitätsklinikum Düsseldorf
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: - Levodopa treatment for at least 3 months prior to the first measurement - Ability to understand the study procedure - Planned THS surgery for the treatment of idiopathic Parkinson's syndrome - Eligible for MRI measurement - Informed consent, signed and dated by the subject or, in the case of motor impairment, by an independent witness

Exclusion criteria

Exclusion criteria: - Presence of a legally authorized representative - Presence of conditions other than idiopathic Parkinson's disease that may worsen motor or cognitive abilities, such as corticobasal syndrome, multisystem atrophy, dementia, severe arthritis, drug/alcohol abuse, Alzheimer's disease, stroke, or similar conditions - Inability to remain seated in the MEG scanner without involuntary movements producing artifacts - Inability to undergo MRI scanning, e.g., metal implants or tattoos containing metal - Past or present participation in pharmacologic clinical trials related to idiopathic Parkinson's syndrome - Claustrophobia - Unable to tolerate levodopa medication withdrawal for at least 12 hours (including dysphagia, tendency to fall) - Inability to walk

Design outcomes

Primary

MeasureTime frame
i) Evaluation of the sensitivity of active and passive sensor-based assessments to detect changes in clinical/motor symptoms in IPS patients upon treatment with deep-brain stimulation. ii) Investigation of structural and functional neuroimaging correlates as measured using MRI and MEG that underlie generation of PD motor symptoms as measured using sensor-based assessments.

Secondary

MeasureTime frame
Identifying sensor-based assessments that are most sensitive to the effects of levodopa medication.

Countries

Germany

Contacts

Public ContactJürgen Dukart

Universitätsklinikum Düsseldorf, Institut für Systemische Neurowissenschaften

dukart@uni-duesseldorf.de+49 2461 61-3187

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026